194 related articles for article (PubMed ID: 22948497)
1. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.
Charles D; Brashear A; Hauser RA; Li HI; Boo LM; Brin MF;
Clin Neuropharmacol; 2012; 35(5):208-14. PubMed ID: 22948497
[TBL] [Abstract][Full Text] [Related]
2. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
3. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Coleman C; Hubble J; Schwab J; Beffy JL; Picaut P; Morte C
Int J Neurosci; 2012 Jul; 122(7):358-62. PubMed ID: 22356470
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.
Naumann M; Carruthers A; Carruthers J; Aurora SK; Zafonte R; Abu-Shakra S; Boodhoo T; Miller-Messana MA; Demos G; James L; Beddingfield F; VanDenburgh A; Chapman MA; Brin MF
Mov Disord; 2010 Oct; 25(13):2211-8. PubMed ID: 20737546
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
[TBL] [Abstract][Full Text] [Related]
8. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
Dunne JW; Gracies JM; Hayes M; Zeman B; Singer BJ;
Clin Rehabil; 2012 Sep; 26(9):787-97. PubMed ID: 22308557
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
[TBL] [Abstract][Full Text] [Related]
11. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF
J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
Carruthers A; Bruce S; de Coninck A; Connolly S; Cox SE; Davis PG; Campo A; Lei X; Somogyi C; Lee E; McLean H; Beddingfield F
Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
[TBL] [Abstract][Full Text] [Related]
17. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.
Lew MF; Brashear A; Dashtipour K; Isaacson S; Hauser RA; Maisonobe P; Snyder D; Ondo W
Int J Neurosci; 2018 Jul; 128(7):619-626. PubMed ID: 29343142
[TBL] [Abstract][Full Text] [Related]
18. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
20. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
Comella CL; Jankovic J; Shannon KM; Tsui J; Swenson M; Leurgans S; Fan W;
Neurology; 2005 Nov; 65(9):1423-9. PubMed ID: 16275831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
